OTCMKTS:PTCHF PureTech Health (PTCHF) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free PTCHF Stock Alerts $2.70 +0.02 (+0.75%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.65▼$2.7050-Day Range$2.31▼$2.8552-Week Range$1.69▼$3.10Volume77,819 shsAverage Volume35,930 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get PureTech Health alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About PureTech Health Stock (OTCMKTS:PTCHF)PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Read More PTCHF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTCHF Stock News HeadlinesApril 9, 2024 | bizjournals.comPureTech’s founding CEO takes new role as head of Boston biotechMarch 23, 2024 | seekingalpha.comPureTech Health: Repeat What WorksApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 13, 2024 | lse.co.ukPureTech Health celebrates drug designation for LYT-200 from US FDAMarch 13, 2024 | markets.businessinsider.comPureTech Health Gets FDA's Orphan Drug Designation For LYT-200 In Acute Myeloid LeukemiaFebruary 24, 2024 | finance.yahoo.comPureTech Health plc (PTCHF)December 20, 2023 | finance.yahoo.comPureTech Year End Update and Outlook for 2024December 16, 2023 | morningstar.comPureTech Health PLC PRTCApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.August 29, 2023 | lse.co.ukPureTech narrows interim loss despite "stormy market challenges"August 1, 2023 | marketwatch.comPureTech Health Gets $11.4Mln to Advance Development of LYT-300June 13, 2023 | finance.yahoo.comResults of PureTech's Annual General MeetingJune 7, 2023 | lse.co.ukPureTech Health's Akili launches ADHD immersive treatment in USMay 9, 2023 | finance.yahoo.comPureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease WeekMay 4, 2023 | finance.yahoo.comPureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based TherapeuticApril 29, 2023 | finance.yahoo.comFull Year 2023 PureTech Health PLC Earnings CallApril 28, 2023 | lse.co.ukPureTech Health yearly loss widens but remains optimisticMarch 25, 2023 | proactiveinvestors.comNike, UBS, MGC Pharmaceuticals, NVIDIA, Travelzoo top the analyst calls of the weekMarch 21, 2023 | lse.co.ukPureTech Health says Karuna KArXT trial receives positive resultsFebruary 14, 2023 | finance.yahoo.comPureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum DepressionJanuary 21, 2023 | reuters.comPRTC.L - | Stock Price & Latest News | ReutersJanuary 13, 2023 | uk.finance.yahoo.comPureTech Health plc (PRTC.L)November 30, 2022 | msn.comPureTech Announces New Therapeutic Candidate LYT-310, An Oral CBD ProdrugNovember 30, 2022 | finance.yahoo.comPureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ PlatformNovember 1, 2022 | finance.yahoo.comPureTech to Present at the Credit Suisse 31st Annual Healthcare ConferenceOctober 13, 2022 | finance.yahoo.comThe Petri Dish: 1910 Genetics hires CBO; PureTech calls off mergerOctober 11, 2022 | lse.co.ukPureTech Health takeover talks with Nektar Therapeutics endSee More Headlines Receive PTCHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:PTCHF CUSIPN/A CIK1782999 Webwww.puretechhealth.com Phone(617) 482-2333FaxN/AEmployees111Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Spencer BallSenior Vice President of Human ResourcesMs. Aleksandra Filipovic M.D.Ph.D., Head of OncologyMs. Cheryl Murphy Ph.D.Head of Grants Management & StrategyMs. Anita Terpstra J.D.Ph.D., Senior VP & Head of Intellectual PropertyMr. Dilip KodiraHead of Data ScienceMs. Anne Burkhardt Ph.D.Head of ResearchDr. Julie Krop M.D. (Age 58)Chief Medical Officer Ms. Joy Bauer M.S.RDN, Chief Nutrition OfficerMr. Robert Lyne (Age 41)Chief Portfolio Officer Mr. William Berry CPAControllerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors PTCHF Stock Analysis - Frequently Asked Questions How have PTCHF shares performed in 2024? PureTech Health's stock was trading at $2.38 on January 1st, 2024. Since then, PTCHF stock has increased by 13.4% and is now trading at $2.70. View the best growth stocks for 2024 here. Are investors shorting PureTech Health? PureTech Health saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 48,500 shares, a decrease of 29.1% from the March 31st total of 68,400 shares. Based on an average daily volume of 6,600 shares, the days-to-cover ratio is currently 7.3 days. View PureTech Health's Short Interest. How do I buy shares of PureTech Health? Shares of PTCHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PTCHF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PureTech Health plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
